Papillomavirus E6 oncoprotein up-regulates occludin and ZO-2 expression in ovariectomized mice epidermis

Experimental Cell Research

Volumn 319, Issue 17, 2013, Pages 2588-2603

  Hernández Monge, Jesús ^a   Garay, Erika ^b   Raya Sandino, Arturo ^a   Vargas Sierra, Orlando ^a   Díaz Chávez, José ^c   Popoca Cuaya, Marco ^a   Lambert, Paul F ^d   González Mariscal, Lorenza ^a   Gariglio, Patricio ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b DEPARTAMENTO DE INGENIERÍA GENÉTICA   (Mexico)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

E6; Epidermis; Estrogen; HPV; MDCK; Progesterone; Tight junction

Indexed keywords

ESTRADIOL; OCCLUDIN; PROGESTERONE; PROTEIN E6; PROTEIN ZO2;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; CELL NUCLEUS; CONTROLLED STUDY; EPIDERMIS; FEMALE; GENETIC TRANSFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; RISK FACTOR; TRANSGENIC MOUSE; UPREGULATION;

EID: 84885372850     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.07.028     Document Type: Article

References (69)

1. Apple R.J., Erlich H.A., et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat. Genet. 1994, 6(2):157-162.
2. Arbeit J.M., Howley P.M., et al. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc. Natl. Acad. Sci. USA 1996, 93(7):2930-2935.
3. Ben-Or S. Morphological and functional development of the ovary of the mouse. I. Morphology and histochemistry of the developing ovary in normal conditions and after FSH treatment. J. Embryol. Exp. Morphol. 1963, 11:1-11.
4. Brake T., Lambert P.F. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc. Natl. Acad. Sci. USA 2005, 102(7):2490-2495.
5. Brandner J.M., Kief S., et al. Organization and formation of the tight junction system in human epidermis and cultured keratinocytes. Eur. J. Cell Biol. 2002, 81(5):253-263.
6. Bullough H.F. Epidermal thickness following oestrone injections in the mouse. Nature 1947, 159(4029):101.
7. Caligioni C.S. Assessing reproductive status/stages in mice. Curr. Protocols Neurosci. 2009, (Appendix 4-Appendix 4I) 48:A.4I.1-A.4I.8.
8. Castoria G., Migliaccio A., et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 2001, 20(21):6050-6059.
9. Cheng Y.H., Imir A., et al. SP1 and SP3 mediate progesterone-dependent induction of the 17beta hydroxysteroid dehydrogenase type 2 gene in human endometrium. Biol. Reprod. 2006, 75(4):605-614.
10. Chlenski A., Ketels K.V., et al. zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. Int. J. Cancer 1999, 83(3):349-358.
11. Das B.C., Sharma J.K., et al. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J. Med. Virol. 1992, 36(4):239-245.
12. Elias P.M. Stratum corneum defensive functions: an integrated view. J. Invest. Dermatol. 2005, 125(2):183-200.
13. Faivre E.J., Daniel A.R., et al. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol. Endocrinol. 2008, 22(4):823-837.
14. Furuse M., Hata M., et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell Biol. 2002, 156(6):1099-1111.
15. Geffroy N., Guedin A., et al. Cell cycle regulation of breast cancer cells through estrogen-induced activities of ERK and Akt protein kinases. Mol. Cell. Endocrinol. 2005, 237(1-2):11-23.
16. Goldhar A.S., Duan R., et al. Progesterone induces expression of the prolactin receptor gene through cooperative action of Sp1 and C/EBP. Mol. Cell. Endocrinol. 2011, 335(2):148-157.
17. Gonzalez-Mariscal L., Betanzos A., et al. Tight junction proteins. Prog. Biophys. Mol. Biol. 2003, 81(1):1-44.
18. Gonzalez-Mariscal L., Diaz Coranguez M., Quiros M. Regulation of tight junctions for therapeutic advantages. In: Tight Junctions in Cancer Metastasis. Martin and Jiang, (Eds.) 2013, vol. 19. Springer, Netherlands.
19. Gonzalez-Mariscal L., Garay E., et al. Identification of claudins by Western blot and immunofluorescence in different cell lines and tissues. Methods Mol. Biol. 2011, 762:213-231.
20. Gonzalez-Mariscal L., Islas S., et al. Molecular characterization of the tight junction protein ZO-1 in MDCK cells. Exp. Cell Res. 1999, 248(1):97-109.
21. Gonzalez-Mariscal L., Ponce A., et al. The tight junction protein ZO-2 has several functional nuclear export signals. Exp. Cell Res. 2006, 312(17):3323-3335.
22. Gonzalez-Mariscal L., Quiros M., Diaz-Coranguez M., Bautista P. Tight junctions. Current Frontiers and Perspectives in Cell Biology 2012, InTech, NS.
23. Gorodeski G.I. Estrogen increases the permeability of the cultured human cervical epithelium by modulating cell deformability. Am. J. Physiol. 1998, 275(3, Pt 1):C888-C899.
24. Grm H.S., Banks L. Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. J. Gen. Virol. 2004, 85(Pt 10):2815-2819.
25. Groten T., Pierce A.A., et al. 17 beta-estradiol transiently disrupts adherens junctions in endothelial cells. FASEB J. 2005, 19(10):1368-1370.
26. Gruber C.J., Gruber D.M., et al. Anatomy of the estrogen response element. Trends Endocrinol. Metab. 2004, 15(2):73-78.
27. Gumbiner B., Lowenkopf T., et al. Identification of a 160-kDa polypeptide that binds to the tight junction protein ZO-1. Proc. Natl. Acad. Sci. USA 1991, 88(8):3460-3464.
28. Imhof A., Schuierer M., et al. Transcriptional regulation of the AP-2alpha promoter by BTEB-1 and AP-2rep, a novel wt-1/egr-related zinc finger repressor. Mol. Cell Biol. 1999, 19(1):194-204.
29. Kiyono T., Hiraiwa A., et al. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 1997, 94(21):11612-11616.
30. Kobayashi K., Miwa H., et al. Progesterone maintains amniotic tight junctions during midpregnancy in mice. Mol. Cell. Endocrinol. 2011, 337(1-2):36-42.
31. Lee J.S., Galvin K.M., et al. Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1. Proc. Natl. Acad. Sci. USA 1993, 90(13):6145-6149.
32. Lee S.S., Glaunsinger B., et al. Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J. Virol. 2000, 74(20):9680-9693.
33. Lievano S., Alarcon L., et al. Endothelia of term human placentae display diminished expression of tight junction proteins during preeclampsia. Cell Tissue Res. 2006, 324(3):433-448.
34. Lioni M., Brafford P., et al. Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am. J. Pathol. 2007, 170(2):709-721.
35. Luczka E., Syne L., et al. Regulation of membrane-type 1 matrix metalloproteinase expression by zonula occludens-2 in human lung cancer cells. Clin. Exp. Metastasis 2013.
36. Mankertz J., Tavalali S., et al. Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J. Cell Sci. 2000, 113(Pt 11):2085-2090.
37. Mankertz J., Waller J.S., et al. Gene expression of the tight junction protein occludin includes differential splicing and alternative promoter usage. Biochem. Biophys. Res. Commun. 2002, 298(5):657-666.
38. Mendoza-Rodriguez C.A., Gonzalez-Mariscal L., et al. Changes in the distribution of ZO-1, occludin, and claudins in the rat uterine epithelium during the estrous cycle. Cell Tissue Res. 2005, 319(2):315-330.
39. Morita K., Furuse M., et al. Molecular architecture of tight junctions of periderm differs from that of the maculae occludentes of epidermis. J. Invest. Dermatol. 2002, 118(6):1073-1079.
40. Morita K., Itoh M., et al. Subcellular distribution of tight junction-associated proteins (occludin, ZO-1, ZO-2) in rodent skin. J. Invest. Dermatol. 1998, 110(6):862-866.
41. Nakagawa S., Huibregtse J.M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 2000, 20(21):8244-8253.
42. Nguyen M.M., Nguyen M.L., et al. Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. Mol. Cell. Biol. 2003, 23(24):8970-8981.
43. Nicholson M.D., Lindsay L.A., et al. Ovarian hormones control the changing expression of claudins and occludin in rat uterine epithelial cells during early pregnancy. Acta Histochem. 2010, 112(1):42-52.
44. Owen G.I., Richer J.K., et al. Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem. 1998, 273(17):10696-10701.
45. Riley R.R., Duensing S., et al. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 2003, 63(16):4862-4871.
46. Scheffner M., Werness B.A., et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63(6):1129-1136.
47. Schiffman M.H., Haley N.J., et al. Biochemical epidemiology of cervical neoplasia: measuring cigarette smoke constituents in the cervix. Cancer Res. 1987, 47(14):3886-3888.
48. Seto E., Lewis B., et al. Interaction between transcription factors Sp1 and YY1. Nature 1993, 365(6445):462-464.
49. Shai A., Brake T., et al. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res. 2007, 67(4):1626-1635.
50. Sheth P., Basuroy S., et al. Role of phosphatidylinositol 3-kinase in oxidative stress-induced disruption of tight junctions. J. Biol. Chem. 2003, 278(49):49239-49245.
51. Simoncini T., Hafezi-Moghadam A., et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407(6803):538-541.
52. Simonson S.J., Difilippantonio M.J., et al. Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential. Cancer Res. 2005, 65(18):8266-8273.
53. Song S., Pitot H.C., et al. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J. Virol. 1999, 73(7):5887-5893.
54. Storrs C.H., Silverstein S.J. PATJ, a tight junction-associated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isoform 18 E6. J. Virol. 2007, 81(8):4080-4090.
55. Tang M., Mazella J., et al. Progesterone receptor activates its promoter activity in human endometrial stromal cells. Mol. Cell. Endocrinol. 2002, 192(1-2):45-53.
56. Thomas M., Glaunsinger B., et al. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 2001, 20(39):5431-5439.
57. Troy T.C., Arabzadeh A., et al. Claudin immunolocalization in neonatal mouse epithelial tissues. Cell Tissue Res. 2007, 330(2):381-388.
58. Troy T.C., Li Y., et al. The temporal and spatial expression of Claudins in epidermal development and the accelerated program of epidermal differentiation in K14-CaSR transgenic mice. Gene Expression Patterns 2007, 7(4):423-430.
59. Tsuchiya S., Tanaka S., et al. Identification and characterization of a novel progesterone receptor-binding element in the mouse prostaglandin E receptor subtype EP2 gene. Genes Cells 2003, 8(9):747-758.
60. Turksen K., Troy T.C. Permeability barrier dysfunction in transgenic mice overexpressing claudin 6. Development 2002, 129(7):1775-1784.
61. Uotinen N., Puustinen R., et al. Distribution of progesterone receptor in female mouse tissues. Gen. Comp. Endocrinol. 1999, 115(3):429-441.
62. Uzuka M., Nakajima K., et al. Estrogen receptor in the mouse skin. Biochim. Biophys. Acta 1978, 544(2):329-337.
63. Watson R.A., Rollason T.P., et al. Changes in expression of the human homologue of the Drosophila discs large tumour suppressor protein in high-grade premalignant cervical neoplasias. Carcinogenesis 2002, 23(11):1791-1796.
64. Weinstein-Oppenheimer C.R., Burrows C., et al. The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. Cancer Biol. Ther. 2002, 1(3):256-262.
65. Werness B.A., Levine A.J., et al. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248(4951):76-79.
66. Ye L., Martin T.A., et al. Biphasic effects of 17-beta-estradiol on expression of occludin and transendothelial resistance and paracellular permeability in human vascular endothelial cells. J. Cell. Physiol. 2003, 196(2):362-369.
67. Zuo L., Li W., et al. Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway. Breast Cancer Res. 2010, 12(3):R34.
68. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991, 184(1):9-13.
69. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta 1996, 1288(2):F55-F78.